Key Takeaways
- Foundayo (active ingredient orforglipron) is an oral small-molecule GLP-1 receptor agonist rather than a peptide, allowing reliable absorption with or without food at any time of day.
- Approved US tablet strengths step up every 30 days across six doses: 0.8mg, 1.6mg, 3mg, 6mg, 12mg, and 17.2mg once daily.
- In the 72-week Phase 3 ATTAIN-1 trial, participants achieved 11%–12% mean body weight reduction, with 55% losing at least 10% of starting weight.
- Unlike the oral Wegovy pill, Foundayo requires zero morning fasting or water limits — making daily adherence simpler for busy schedules.
Foundayo (orforglipron) marks a major pharmacological milestone in metabolic care. Developed by Eli Lilly, it belongs to the same GLP-1 receptor agonist drug class as semaglutide, yet uses a non-peptide small-molecule structure designed specifically to survive digestion effortlessly.
How Foundayo Differs from Other GLP-1 Tablets
Traditional GLP-1 medications like semaglutide are large peptide chains that stomach acid rapidly breaks down unless taken under strict fasting conditions. Because orforglipron is a small chemical molecule, it binds GLP-1 receptors in the pancreas, gut, and brain without needing an absorption buffer:
| Feature | Foundayo (Orforglipron) | Wegovy Pill (Oral Semaglutide) |
|---|---|---|
| Molecule type | Non-peptide small molecule | Peptide + SNAC absorption enhancer |
| Fasting requirement | None — take with or without food | Mandatory overnight fast + 30-min wait |
| Water restriction | None — drink normally | Max 120mL plain water at dosing |
| Time of day | Any consistent time (morning or evening) | Morning immediately upon waking |
| Titration strengths | 0.8mg -> 1.6mg -> 3mg -> 6mg -> 12mg -> 17.2mg | 1.5mg -> 4mg -> 9mg -> 25mg |
For a full step-by-step schedule, see our Foundayo dosing & titration guide.
Clinical Trial Weight Loss & Side Effects (ATTAIN-1)
In the 72-week ATTAIN-1 New England Journal of Medicine trial:
- Adults achieved 11% to 12% average body weight loss at the highest investigational dose.
- 55% lost at least 10% of baseline weight, and 18% lost 20% or more.
As with injectable GLP-1 therapies, mild-to-moderate gastrointestinal symptoms (nausea, diarrhea, constipation, or dyspepsia) occurred in roughly 60%–69% of participants, primarily during 30-day dose escalations before settling at maintenance.
Eligibility & Safety Contraindications
Foundayo follows standard medical weight-management criteria (BMI ≥30, or BMI ≥27 with a weight-related condition such as hypertension, dyslipidemia, or prediabetes/type 2 diabetes). It is contraindicated in pregnancy, breastfeeding, and anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Because orforglipron delays gastric emptying during dose increases, patients taking oral contraceptive pills are advised to add barrier contraception for 4 weeks when starting and after each dose step.
References
- Wharton S, Aronne LJ, Stefanski A, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1). N Engl J Med. 2025.
- Eli Lilly and Company. Foundayo (orforglipron) Prescribing Information. 2026.
Related Clinical Guides
Your personalizedweight care plan
Clinician-prescribed GLP-1 & metabolic care, 100% online.